Rare Cancers Australia has welcomed the December extended
listing of Eisai's HALAVEN (eribulin) for the treatment of patients living with
The Pharmaceutical Benefits Advisory Committee actually
recommended the new listing in November last year largely on the basis unmet
medical need and low financial impact. The therapy was already listed for the
treatment of advanced breast cancer.
HALAVEN is for the treatment of liposarcoma, a malignancy of
fat cells, which cannot be removed with surgery and for which prior treatment
with chemotherapy has failed.
According to Rare Cancers Australia chief executive, Richard
Vines, “In Australia, rare cancers remain an area of significant unmet clinical
need in contrast to other common cancers such as breast, bowel and lung.
"The PBS listing of HALAVEN for people living with
advanced liposarcoma, who have unfortunately failed on previous chemotherapy
and can’t have their tumour surgically removed, is a welcome and affordable
advance for Australian patients. It is great to see companies such as Eisai
working with the Government to get much needed treatment to Australians living
a rare cancer.”
“Eisai welcomes the availability of Halaven on the PBS from
1 December, which provides patients in Australia with a treatment option for
their previously treated, advanced liposarcoma," said Jaime McCoy,
director of Eisai Australia.
"We continue to be committed to the discovery,
development and access to treatments for rare cancers like advanced
“The survival outcomes for patients with incurable
liposarcoma can be poor and additional treatments are needed. HALAVEN
represents an important addition to the options for clinicians treating these
patients with advanced liposarcoma,” said Professor David Thomas, director of
The Kinghorn Cancer Centre and head of the Cancer Division at the Garvan
Institute of Medical Research.
This article was originally published on PharmaDispatch. You can read the original article here.